Document is current
Any future updates will be listed below
-
Authors
Halioua-Haubold, Celine-Lea
Jolly, Jasleen K. http://orcid.org/0000-0001-9878-4621
Smith, James A. http://orcid.org/0000-0003-2634-0268
Pinedo-Villanueva, Rafael http://orcid.org/0000-0002-4723-5128
Brindley, David A.
MacLaren, Robert E.
- License Information
-
More Information
Article History
Received: 29 May 2018
Revised: 13 September 2018
Accepted: 15 March 2019
First Online: 17 July 2019
Compliance with ethical standards
:
: REM is a Founder of Nightstar Ltd and a consultant to Spark Therapeutics Inc. REM is acting as an independent academic and neither Nightstar nor Spark had any role in the conception or execution of this research study. CLHH does not receive funding or other incentives from NightStar, Spark Therapeutics, or any other entity with commercial interests in Choroideremia gene therapy. JKJ, JAS, RPV and DAB have no conflicts.
